Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers.

Mondaca S, Offin M, Borsu L, Myers M, Josyula S, Makhnin A, Shen R, Riely GJ, Rudin CM, Ladanyi M, Yu HA, Li BT, Arcila ME.

Acta Oncol. 2019 Jul 26:1-6. doi: 10.1080/0284186X.2019.1645354. [Epub ahead of print]

PMID:
31347936
2.

Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Offin M, Chan JM, Tenet M, Rizvi HA, Shen R, Riely GJ, Rekhtman N, Daneshbod Y, Quintanal-Villalonga A, Penson A, Hellmann MD, Arcila ME, Ladanyi M, Pe'er D, Kris MG, Rudin CM, Yu HA.

J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30466-6. doi: 10.1016/j.jtho.2019.06.002. [Epub ahead of print]

PMID:
31228622
3.

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers.

Offin M, Guo R, Wu SL, Sabari J, Land JD, Ni A, Montecalvo J, Halpenny DF, Buie LW, Pak T, Liu D, Riely GJ, Hellmann MD, Benayed R, Arcila M, Kris MG, Rudin CM, Li BT, Ladanyi M, Rekhtman N, Drilon A.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00386. Epub 2019 May 16. No abstract available.

4.

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer.

Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, Lockwood WW, Arcila ME, Rudin CM, Drilon A, Yu HA, Riely GJ, Somwar R, Ladanyi M.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00011. Epub 2019 May 10. No abstract available.

5.

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.

Benayed R, Offin M, Mullaney K, Sukhadia P, Rios K, Desmeules P, Ptashkin R, Won H, Chang J, Halpenny D, Schram AM, Rudin CM, Hyman DM, Arcila ME, Berger MF, Zehir A, Kris MG, Drilon A, Ladanyi M.

Clin Cancer Res. 2019 Aug 1;25(15):4712-4722. doi: 10.1158/1078-0432.CCR-19-0225. Epub 2019 Apr 26.

PMID:
31028088
6.

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M.

J Thorac Oncol. 2019 May;14(5):802-815. doi: 10.1016/j.jtho.2018.12.038. Epub 2019 Mar 1.

PMID:
30831205
7.

Liquid biopsy guided precision therapy for lung cancers.

Xu C, Offin M, Paik PK, Li BT.

J Thorac Dis. 2018 Nov;10(Suppl 33):S4173-S4175. doi: 10.21037/jtd.2018.11.02. No abstract available.

8.

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.

Sabari JK, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, Clarke S, Diakos CI, Datta S, Tandon N, Martinez A, Myers ML, Makhnin A, Leger Y, Yu HA, Paik PK, Chaft JE, Kris MG, Jeon JO, Borsu LA, Ladanyi M, Arcila ME, Hernandez J, Henderson S, Shaffer T, Garg K, DiPasquo D, Raymond CK, Lim LP, Li M, Hellmann MD, Drilon A, Riely GJ, Rusch VW, Jones DR, Rimner A, Rudin CM, Isbell JM, Li BT.

J Natl Cancer Inst. 2018 Nov 28. doi: 10.1093/jnci/djy156. [Epub ahead of print]

PMID:
30496436
9.

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer.

Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, Sabari JK, Tai H, Mattar M, Khodos I, de Stanchina E, Rudin CM, Kris MG, Arcila ME, Lockwood WW, Drilon A, Ladanyi M, Somwar R.

Clin Cancer Res. 2019 Feb 15;25(4):1248-1260. doi: 10.1158/1078-0432.CCR-18-1640. Epub 2018 Oct 23.

PMID:
30352902
10.

Tumor-Agnostic Drug Development.

Offin M, Liu D, Drilon A.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:184-187. doi: 10.1200/EDBK_200831.

PMID:
30231313
11.

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.

Sabari JK, Leonardi GC, Shu CA, Umeton R, Montecalvo J, Ni A, Chen R, Dienstag J, Mrad C, Bergagnini I, Lai WV, Offin M, Arbour KC, Plodkowski AJ, Halpenny DF, Paik PK, Li BT, Riely GJ, Kris MG, Rudin CM, Sholl LM, Nishino M, Hellmann MD, Rekhtman N, Awad MM, Drilon A.

Ann Oncol. 2018 Oct 1;29(10):2085-2091. doi: 10.1093/annonc/mdy334.

PMID:
30165371
12.

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.

Liu D, Offin M, Harnicar S, Li BT, Drilon A.

Ther Clin Risk Manag. 2018 Jul 20;14:1247-1252. doi: 10.2147/TCRM.S147381. eCollection 2018. Review.

13.

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers.

Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, Drilon A, Kris MG, Rudin CM, Schultz N, Arcila ME, Ladanyi M, Riely GJ, Yu H, Hellmann MD.

Clin Cancer Res. 2019 Feb 1;25(3):1063-1069. doi: 10.1158/1078-0432.CCR-18-1102. Epub 2018 Jul 25.

PMID:
30045933
14.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

PMID:
30017832
15.

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG.

J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):362.

16.

Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation.

Xiao W, Yabe M, Offin M, Khattar P, Baik J, Daley RJ, Pappacena JJ, Roshal M, Zhang Y, Tallman MS, Cai SF.

Blood Adv. 2018 Jul 10;2(13):1517-1521. doi: 10.1182/bloodadvances.2018016675. No abstract available.

17.

Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers.

Offin M, Somwar R, Rekhtman N, Benayed R, Chang JC, Plodkowski A, Lui AJW, Eng J, Rosenblum M, Li BT, Riely GJ, Rudin CM, Kris MG, Travis W, Drilon A, Arcila ME, Ladanyi M, Yu HA.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4. No abstract available.

18.

Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA.

Offin M, Chabon JJ, Razavi P, Isbell JM, Rudin CM, Diehn M, Li BT.

J Oncol. 2017;2017:4517834. doi: 10.1155/2017/4517834. Epub 2017 Mar 14. Review.

19.

Association Among Hypoxemia, Patent Foramen Ovale, and Mediastinal Germ Cell Tumor: A Case Report.

Offin MD, Menachem J, Squillante C, Ky B, Vaughn D, Carver J.

Ann Intern Med. 2015 Aug 4;163(3):243-4. doi: 10.7326/L15-5120. No abstract available.

PMID:
26237762
20.

Structured communication: teaching delivery of difficult news with simulated resuscitations in an emergency medicine clerkship.

Lamba S, Nagurka R, Offin M, Scott SR.

West J Emerg Med. 2015 Mar;16(2):344-52. doi: 10.5811/westjem.2015.1.24147. Epub 2015 Mar 12.

21.

Impact of enhanced mobilization of bone marrow derived cells to site of injury.

Hannoush EJ, Sifri ZC, Elhassan IO, Mohr AM, Alzate WD, Offin M, Livingston DH.

J Trauma. 2011 Aug;71(2):283-9; discussion 289-91. doi: 10.1097/TA.0b013e318222f380.

PMID:
21825928
22.

Does beta blockade postinjury prevent bone marrow suppression?

Mohr AM, ElHassan IO, Hannoush EJ, Sifri ZC, Offin MD, Alzate WD, Rameshwar P, Livingston DH.

J Trauma. 2011 May;70(5):1043-9; discussion 1049-50. doi: 10.1097/TA.0b013e3182169326.

23.

β-blockade protection of bone marrow following trauma: the role of G-CSF.

Baranski GM, Offin MD, Sifri ZC, Elhassan IO, Hannoush EJ, Alzate WD, Rameshwar P, Livingston DH, Mohr AM.

J Surg Res. 2011 Oct;170(2):325-31. doi: 10.1016/j.jss.2011.03.059. Epub 2011 Apr 19.

Supplemental Content

Support Center